Focused On-demand Library for 5-hydroxytryptamine receptor 1F

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P30939

UPID:

5HT1F_HUMAN

Alternative names:

Serotonin receptor 1F

Alternative UPACC:

P30939

Background:

The 5-hydroxytryptamine receptor 1F, also known as the Serotonin receptor 1F, plays a pivotal role in neurotransmission and neuromodulation. This receptor is a G-protein coupled receptor (GPCR) that binds to serotonin, a key neurotransmitter involved in regulating mood, appetite, and sleep. Activation of this receptor leads to a conformational change, initiating signaling pathways that ultimately inhibit adenylate cyclase activity, thereby modulating cellular responses.

Therapeutic significance:

Understanding the role of 5-hydroxytryptamine receptor 1F could open doors to potential therapeutic strategies. Its involvement in serotonin signaling makes it a potential target for treating disorders related to mood, appetite, and sleep regulation.